TABLE 2.
The data of response to ALK inhibitors in patients with uncommon fusion partners
| No. | Sex | Age | Partner | VAF, % | 1st Line | Best Response |
TST 1 (months) |
2nd line | Best response |
TST 2 (months) |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 | M | 56 | ZNF362 | 4.4 | Alectinib | PR a | 9.9 | Clinical trial | _ | _ |
| 32 | M | 52 | TPM3 | 12.2 | Crizotinib | SD | 18.4 | _ | _ | _ |
| 34 | F | 51 | CLTC | 44.4 | Crizotinib | PR a | 11.7 | Ceritinib | SD a | 3.5 |
| 53 | F | 55 | TRAF3/AE000662.92 | 6.94/6.44 | Alectinib | PR a | 8.7 | chemotherapy | SD a | 2.4 |
| 54 | M | 47 | LINC01247 | 3.72 | Crizotinib | PD | 4.5 | UN | _ | _ |
| 59 | M | 67 | MYH10 | 13.2 | Crizotinib | SD a | 9.9 | Ceritinib | PR | 23.0 |
| 65 | F | 37 | ST6GAL2RGPD4 | 4.1 | Crizotinib | PR | 9.2 | _ | _ | _ |
| 72 | M | 38 | NEGR1/LINC01360 | 10 | Crizotinib | PR a | 4.5 | Ceritinib | SD | 4.2 |
| 75 | M | 59 | NEB | 5.1 | Crizotinib | PR a | 7.7 | Alectinib | PR | 26.8 |
| 102 | M | 31 | MAP4K3 | 5.6 | Crizotinib | PD | 1.6 | Brigatinib | SD | 4.4 |
| 106 | F | 72 | IGR(C16orf47) | 6.4 | Crizotinib | SD | 15.9 | _ | _ | _ |
| 123 | M | 45 | PLXNA‐4 | 7.9 | Crizotinib | PR a | 17 | Clinical trial | _ | _ |
| 146 | F | 20 | HIP1 | 39.1 | Alectinib | PR a | 14.2 | UN | _ | _ |
| 36 | F | 65 | EML4/THADA | 7.8/11.6 | Alectinib | SD | 20.8 | _ | _ | _ |
| 62 | F | 45 | EML4/CLIP4 | 18.29/22.95 | Crizotinib | PR a | 5.8 | Ceritinib | PD | 1.0 |
| 79 | M | 74 | EML4/TLK2 | 17.79/24.84 | Crizotinib | PR a | 6 | UN | _ | _ |
| 81 | M | 62 | EML4/LINC01317 | 19.9/17.4 | Crizotinib | SD a | 10 | Brigatinib | SD a | 5.0 |
| 86 | M | 37 | EML4/NRXN1 | 26.6/20.6 | Crizotinib | PD | 1.2 | chemotherapy | PR | 4.2 |
| 97 | M | 63 | EML4/DPF1&PPP1R14A | 8.3/9.5 | Crizotinib | PR | 24.9 | _ | _ | _ |
| 107 | M | 50 | EML4/ABCA3 | 6.04/3.25 | Crizotinib | SD a | 5.3 | UN | _ | _ |
| 110 | M | 62 | EML4/TCF7L1 | 5.42/7.03 | Crizotinib | PR | 21.8 | _ | _ | _ |
| 125 | F | 51 | EML4/PPP1R21 | 28.4/26.7 | Crizotinib | SD | 9.3 | _ | _ | _ |
Note: TNM stages of all patients were IV, except that of patient 53 was III. The histology of all patients was adenocarcinoma, except that of patient 86 was squamous carcinoma.
Abbreviations: ICI indicates immune check point; PD, progressive disease; PR, Partial response; SD, Stable disase; TST, Time since treatment; UN, Unknown; VAF, variant allele fraction.
a
Patients had progressive diseases after responding to ALK inhibitors.